Press Release
ZUBR Has Become a Leader in the NMN Industry at Home and Abroad

As the global economy continues to grow and life expectancy continues to rise, the proportion of elderly people aged 65 years and above continues to increase, and global attention to health issues continues to increase. The life expectancy issue has become one of the ultimate problems that mankind has continued to strive to solve in the history of mankind. In recent years, global academic research has shown that NMN has become a consensus anti-aging health care product.
The full name of NMN is β-nicotinamide mononucleotide, which is the precursor for the synthesis of NAD+ (coenzyme I) in the human body. Since NAD+ is a coenzyme for hundreds of important metabolic enzymes in cells, it also participates in many important cellular processes as a signal molecule. It is closely related to energy metabolism, glycolysis, DNA replication and other activities. NMN can increase the level of NAD+ in the body and is considered a health product with anti-aging functions. Compared with other products, NMN products enhance NAD+ and have the advantages of non-toxic side effects and high conversion efficiency. At present, the academic community has confirmed that NMN has the following 10 major functions: support NAD+ production (NAD+ is an indicator of aging in the body), activate longevity protein/gene SIRTUINS, repair DNA damage, support energy production, enhance metabolism, help enhance physical endurance and vitality, and helps improve blood vessel and muscle physiology, helps weight management, helps brain and heart health, helps improve insulin sensitivity, etc.
As one of the world-class academic achievements, Professor David Sinclair of Harvard University used NMN raw materials and published the research results of NAD+ reversing blood aging in the top academic journal “Cell”. From the age of 30, the NAD+ content in the body decreases significantly. At the age of 60, the level of NAD+ is less than a quarter of that of young people. This means that after 60 years of age, there are many biochemical and metabolic reactions in the human body that cannot be efficiently carried out. Therefore, the older the age, the more health problems become.

How to effectively supplement NMN? According to the FDA’s principle of equivalence, a 70Kg adult should be supplemented with 300mg of NMN per day, and an adult with the same amount of NMN needs to eat 32~128kg of edamame, or 54~240kg of broccoli. It is less efficient to supplement NMN through food sources in nature, and NMN products can achieve this effect faster. After taking NMN in the human body, the study found that the NAD+ content in the body increased significantly after 5 minutes, and the supplement effect was significantly improved.
ZUBR® from the United States is a high-tech company focusing on anti-aging research and product development for a long time. Headquartered in New York, USA, ZUBR® brand Slogan is Anti-aging From Young, advocating the life concept of “anti-aging while young”. ZUBR® introduces anti-aging explosives such as NMN to the United States, Europe and Asia, bringing a healthy lifestyle of “anti-aging while young” to hundreds of millions of middle-class people around the world. ZUBR® has the core production qualifications of health care products such as FDA, NSF GMP, and has mastered core production technology. According to the laboratory test results of US Pharmatech, ZUBR® NMN developed by biological enzymatic method has the characteristics of high purity, high absorption and conversion rate, and the effective purity is higher than that of products in the same industry.

At present, ZUBR® has many flagship products such as NMN Pro and NMN Honor, and the product line fully meets the needs of different users. Among them, the NMN Pro product comes in small bottles, which is currently the only product on the market with a weekly pack (14 capsules) as a unit, which is especially suitable for urban white-collar people to carry during their daily commuting. Each bottle of NMN Pro contains 14 high-concentration NMN capsules, which can be used for a week, and each time it is taken, it can supplement 340mg NMN and 100mg resveratrol. NMN Honor provides a more powerful dose of NMN, suitable for reuse in the morning at home. It can supplement 480mg of NMN and 100mg of resveratrol each time. Each bottle provides 90 capsules for 45 days of continuous use.
Overseas, ZUBR® has won praise from a large number of users with its excellent product strength. Bryan Gunn, an automotive industry designer from Ohio, USA, said, “After taking it, I feel my body is full of vitality, my sleep quality has unexpectedly improved, and I feel my mind is clearer”. Dean Norris, a fund manager from Wall Street in New York, United States, said, “Day 1: 2 capsules in the morning, the body has a significant reaction in the afternoon, and fatigue is reduced; Day 2: 2 capsules in the morning, I feel more clear-headed; 4, 5 days: One hour after each consumption, you can feel your mind becomes clearer and no longer tired; 6th and 7th days: More energy and weight loss than before.” Peter Gould, a Java development engineer from California, said, “Since taking it, I have been very stable and sustained vitality throughout the day. This is an experience I haven’t had before trying other health foods.”
ZUBR® officially entered the Asian market in 2019, using word of mouth as the lifeline of the company’s survival and development. At the same time, in combination with the actual needs of the Asian market, the product price is reduced to a level that can be purchased by the general public while meeting the effective dose. We have reason to believe that ZUBR® will soon become the leading brand in the field of anti-aging health food.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
AI Labs leverages Google’s Gemini AI to bring market analysis into its Chatbot
Singapore – 19/11/2026 – (SeaPRwire) – AI Labs chatbot, AIV, combines crypto and equity market analysis with trading strategies and risk assessments, as it reports about 700,000 active users, daily trading volumes of US$50-100M a day, and total value locked (TVL) of $80-100M across its platform.
AI Labs is using Google‘s Gemini artificial intelligence technology to power its AIV Chatbot, enabling users to explore cryptocurrency and equity markets through conversational analysis, trading scenarios and investment risk assessments.
The chatbot goes beyond conventional price summaries by incorporating technical indicators, business fundamentals, institutional sentiment and market catalysts. It can also outline potential entry and exit levels, evaluate alternative trading strategies and identify risks that could undermine an investment thesis.

“Our aim is to help users understand not just a market view, but the reasoning and risks behind it,“ said Ryan Chi, founder and chief executive officer of AI Labs. “AIV brings those elements into a conversation, so users can explore different scenarios rather than rely on a standalone buy or sell signal.“
Examples provided by the company demonstrate the chatbot‘s capabilities across multiple assets. A Bitcoin query generates a seven-day trading scenario incorporating technical support levels, ETF flows and downside risks. An Nvidia analysis combines technical indicators with growth prospects, valuation and earnings volatility, while a Solana example explores long-short strategies and liquidation risks.
“The important distinction is between generating a trading idea and explaining the assumptions and risks behind it,“ said Terry Tan, an advisor to AI Labs. “AI-powered tools should support independent judgment by helping users understand both opportunities and potential downside scenarios.“
The company says it is continuing to onboard new users and is committed to making every reasonable effort to sustain the high levels of trading activity at US$50-100M daily as it expands its AI-powered financial services.
Media Contact
Company: AI Labs
Contact: Media Team
Email: ryan@academic-labs.org
Website: https://ai-labs.live/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
China Medical System’s Innovative Oral Drug for Vitiligo, Povorcitinib Enrolls First Patient in China Phase III Clinical Trial
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”, 867.HK/8A8.SG) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited), has enrolled the first patient in the China Phase III clinical trial of its innovative oral JAK1 inhibitor Povorcitinib Phosphate Tablets (“povorcitinib” or the “Product”) for the treatment of vitiligo on 19 November 2026.
The trial is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of povorcitinib in Chinese adult patients with non-segmental vitiligo. Led by Professor Li Chunying of the First Affiliated Hospital of Air Force Medical University, the study is planned to be conducted at approximately 44 clinical research centers across China and is expected to enroll approximately 174 patients with non-segmental vitiligo.
The Product has previously completed a series of clinical trials related to pharmacokinetics and bioequivalence in healthy participants in China, and has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”). This certification has the potential to accelerate its development and review process. The enrollment of the first patient in this China Phase III clinical trial marks a pivotal stage in the Product’s clinical development in China and lays a foundation for further evaluating its efficacy and safety in Chinese patients with vitiligo.
Addressing Unmet Clinical Needs in Vitiligo with Novel and Differentiated Treatment Options
Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Currently, treatment options are limited for vitiligo patients who require systemic therapy, and their clinical treatment needs remain inadequately met.
Overactivity of certain proinflammatory cytokines that signal through the JAK-STAT pathway, is believed to drive inflammation and contribute to the pathogenesis and progression of vitiligo. Incyte has announced that Phase III clinical studies outside China of the oral JAK1 inhibitor Povorcitinib Phosphate Tablets in adults with non-segmental vitiligo have met the primary endpoints[2]. If approved in China, the Product has the potential to provide a new oral treatment option for patients with non-segmental vitiligo and, together with Dermavon’s commercialized innovative drug Lumirix® (ruxolitinib phosphate cream), provide vitiligo patients with comprehensive and diversified treatment options, from precise topical intervention to systemic treatment.
Focusing on major skin diseases such as vitiligo, atopic dermatitis and psoriasis, Dermavon has developed an innovative product portfolio covering different disease stages and clinical needs. The enrollment of the first patient in the Phase III clinical trial of povorcitinib in China represents another important milestone in Dermavon’s advancement of local clinical development for global innovative drugs. Going forward, Dermavon will continue to leverage its strong global R&D partnerships and clinical development capabilities in China to accelerate the translation of innovation into clinical application and bring more professional and differentiated treatment options to patients with skin diseases in China.
More Information About Povorcitinib Phosphate Tablets
Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. In addition to vitiligo, the Product has also demonstrated development potential in other indications. Incyte is conducting Phase III clinical trials of povorcitinib for the treatment of prurigo nodularis (PN) in several countries outside China, and has obtained European Commission approval for hidradenitis suppurativa (HS). Dermavon may also consider initiating clinical development of the Product in China for the treatment of additional skin-related diseases.
A subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to China Medical System Holdings Limited (excluding Dermavon and its subsidiaries).
About CMS
CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value.
CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network.
CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development.
Reference
1、China Insights Consultancy (CIC) report
2、Public information on the Incyte official website:https://investor.incyte.com/news-releases/news-release-details/incyte-reports-first-quarter-2026-financial-results-and-provides
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
ONAR’s Largest Acquisition Closed With Two Days Left in Q3
NYC, New York, November 19th, 2026, FinanceWire
ONAR Holding Corporation (OTCID: ONAR) acquired affiliate marketing firm Advertise Purple on September 29, two days before the books closed on its third quarter. That timing left shareholders with an unusual snapshot. ONAR recorded the obligations it took on to buy a business more than three times its size by revenue, while just two days of that business’s sales counted toward the $1.06 million ONAR reported for the quarter.
Had ONAR owned Advertise Purple throughout the quarter, the two businesses would have generated $4.44 million in revenue, according to unaudited figures in CEO Claude Zdanow’s stockholder letter. Over the first nine months of 2026, combined revenue would have totaled $13.52 million, compared with the $3.13 million ONAR reported. Those figures show the historical scale of the business ONAR bought. They exclude interest on the acquisition debt and assume no cost savings from bringing the companies together.
What Advertise Purple brings to ONAR
The first signs of integration are showing up in how the two businesses find customers. JUICE, an ONAR marketing agency, now handles Advertise Purple’s own marketing and has brought it new business, according to Zdanow. Advertise Purple’s sales team, in turn, sends leads to JUICE each month. Its core leadership team stayed on after the acquisition.
ONAR is also introducing its technology to Advertise Purple’s teams and clients, including Cortex, which helps marketers connect advertising activity with online and offline sales. The fourth quarter will give shareholders their first full reporting period to assess how the businesses perform under common ownership.
Why the Nasdaq application matters
ONAR’s reported nine-month revenue rose 68% year over year, and its operating loss narrowed 60%. The company still posted a $3.61 million net loss and used $590,000 in cash from operations. Interest accounted for nearly three-quarters of the net loss, according to ONAR, and most of that interest was noncash.
At September 30, ONAR had $37.7 million in total liabilities, up from $9.7 million at the start of the year. About $16.4 million represented acquisition payments due over time, including an earnout tied to Advertise Purple’s performance. ONAR ended the quarter with a $15.2 million working capital deficit and said its filings continue to identify substantial doubt about its ability to continue as a going concern.
That puts financial weight behind ONAR’s pursuit of a Nasdaq Capital Market listing. A qualifying national exchange listing would automatically convert $11 million in junior secured notes into preferred stock. Without a listing, those notes remain outstanding and mature in March 2028. ONAR has approved a 1-for-250 reverse stock split as part of its listing preparations. The split has yet to take effect, and Nasdaq approval remains uncertain.
For shareholders, the next operating milestone comes with ONAR’s annual report. It will include the first full quarter of Advertise Purple’s revenue and expenses under ONAR ownership, giving investors a clearer view of what the larger business earns and how much cash it uses.
About ONAR Holding Corporation
ONAR (pronounced “Honor”) is an AI-powered marketing platform. ONAR acquires and operates specialist marketing agencies serving middle-market and growth-stage brands across performance marketing, creative, and commerce, and runs them on shared proprietary technology designed to automate up to 70% of manual agency work. Its technology division, ONAR Labs, develops and houses that technology, including ONAR AI, a marketing intelligence platform deployed across the Company’s agencies; Retina AI, a predictive customer intelligence platform; and Cortex, an offline and online sales attribution platform.
Together, these products are designed to make the Company’s teams more productive and to shift agency work from billable hours toward measurable client results. ONAR continues to expand the platform through disciplined acquisitions, including JUICE, Scale Partner, and Advertise Purple.
Learn more at https://www.onar.com/
Contact
President
Craig Fischer
ValueCorp
cf@valuecorptrading.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release1 week ago
Midwest Ragdolls Explains Why Playful Kitten Biting Is Often Misunderstood
-
Press Release2 days ago
OiLChef Wins Restaurant Solution of the Year Award at 2026 Restaurant & Takeaway Innovation Expo
-
Press Release1 week ago
ARCPE Holding, LLC Highlights the Importance of Understanding Local Real Estate Market Conditions
-
Press Release7 days ago
Red Banyan CEO Evan Nierman Leads High-Stakes Communications Workshop at NASDDDS Annual Conference
-
Press Release6 days ago
IntelliVIX Wins Two CES 2027 Innovation Awards, Showcasing Global Competitiveness in Safety AI
-
Press Release6 days ago
Rifstone Capital LLC Advances Institutional Research Platform with Expanded Global Allocation Framework
-
Press Release1 week ago
Dasher Personalized Running Highlights Personalized Half Marathon Training Plans Focused on Injury Prevention and Sustainable Progress
-
Press Release6 days ago
Eurotrace net Unveils New Blockchain Intelligence Research Initiative
